TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Total body weight \>= 50 kg and body mass index (BMI) \>=18 kg/m2 and \<=35 kg/m2~* in good health with no history, or current evidence of clinically significant medical condition of laboratory, ECG or vital sign abnormality~* Sero suitable for challenge virus~Exclusion Criteria:~* History of or currently active symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to first study visit~* Any history or evidence of any clinically significant or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological (including immunosuppression),metabolic, urological, renal, neurological, or psychiatric disease and/or other major disease~* females who are breastfeeding or have been pregnant within 6 months prior to the study or have a positive pregnancy test~* Lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction~* Any significant abnormality altering the anatomy of the nose in a substantial way~* Any clinically significant history of epistaxis (large nosebleeds)~* Any nasal or sinus surgery within 3 months of first study visit~* Evidence of vaccinations within 4 weeks of Day 0~* Receipt of blood or blood products, or loss of 550 mL or more blood within last 3 months~* Receipt of 3 or more investigational drug within last 12 months~* Prior inoculation with a virus from the same virus-family as the challenge~* Prior participation in another HVC study with a respiratory virus in last 3 months~* Use or anticipated use during the conduct of the study of protocol specified concomitant medications~* Systemic antiviral administration within 4 weeks of viral challenge~* Confirmed positive test for drugs of abuse~* History or presence of alcohol addiction, or excessive use of alcohol~* A forced expiratory volume in 1 second (FEV1) \<80%~* Positive HIV, hepatitis B virus, or hepatitis C virus test~* Presence of fever upto 2 days prior to Day 0.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active (Type: EXPERIMENTAL): spray-dried dispersion (SDD) for Oral Suspension
- Placebo (Type: PLACEBO_COMPARATOR): spray-dried dispersion (SDD) for Oral Suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Normal vision at distance, either natural or post corneal laser refractive surgery, with presbyopia in each eye and complaints of poor near vision that impacts activities of daily living~Exclusion Criteria:~* Use of any topical ophthalmic medications, including artificial tears other than the study medications during the study~* Corneal abnormalities in either eye that interfere with visual acuity~* History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery or any intraocular surgery~* Diagnosis of glaucoma or ocular hypertension.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Vehicle Control (Type: EXPERIMENTAL): Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
- Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A (Type: EXPERIMENTAL): Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
- Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B (Type: EXPERIMENTAL): Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
- Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C (Type: EXPERIMENTAL): Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
- Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C (Type: EXPERIMENTAL): Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must give consent to participate in the study and sign and date the IRB approved written informed consent form prior to the initiation of any study procedures~* Subject must be between the ages of 18 and 70~* Subject must have a diagnosis of bipolar I or II.~* Subject must be currently depressed as confirmed by the Mini-International Neuropsychiatric Interview (MINI)~* Subject must have a baseline Montgomery-Asberg Depression Scale (MADRS) score of \>19 and Young Mania Rating Scale (YMRS) score of \<12~* Women of childbearing potential must be nonpregnant/nonlactating and using adequate contraception if sexually active~* Subject must not be using any concomitant psychotropic medications during the acute phase except prn benzodiazepines~Exclusion Criteria:~* Subjects lacks the capacity to provide informed consent~* Subject has currently or previously used divalproex or Dvpx-ER~* Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators~* Subject has any alcohol, cocaine, or cannabis dependence within 3 months of study entry~* Subject has any cocaine, hallucinogens, opiates, crystal methamphetamine, or MMDA abuse within 3 months of study entry

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Divalproex Sodium ER (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed assent and parental permission (age as per local law) obtained at screening before any assessment is performed.~2. Must be 6 to less than 18 years of age at the time of randomization~3. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011 score of ≥ 3, and BSA involvement of ≥10%, at randomization.~4. Subject being regarded by the investigator to be a candidate for systemic therapy.~Exclusion Criteria:~1. Forms of psoriasis other than chronic plaque-type active at randomization~2. Drug-induced psoriasis~3. Ongoing use of prohibited treatments~4. Female subjects of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing and for 16 weeks after stopping study treatment~5. Pregnant or nursing (lactating) females~6. Subjects with total WBC count \<2,500/μL, or platelets \<100,000/μL or neutrophils \<1,500/μL or hemoglobin \<8.5 g/dL at screening~7. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or the IL-17 receptor

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- secukinumab low dose (Type: EXPERIMENTAL): secukinumab low dose
- secukinumab high dose (Type: EXPERIMENTAL): secukinumab high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures;~* Men and women 18 years and older;.~* Established indication to PCI according to the guidelines of American Heart Association and American College of Cardiology;~* Native coronary lesion suitable for drug-eluting stent placement and OCT imaging.~Exclusion Criteria:~* Pregnancy and breast feeding mother;~* Co-morbidity with an estimated life expectancy of \< 50 % at 12 months;~* Scheduled major surgery in the next 6 months;~* Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk;~* Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 30 days~* Cardiogenic shock~* Previous subacute or late coronary stent thrombosis~* Known allergy against ticagrelor, or against clopidogrel, or aspirin~* History of major hemorrhage (intracranial, gastrointestinal, etc.)~* Active pathological bleeding~* Acute or chronic hematologic disorder including a Hemoglobin less than 10 g/L or a platelet count less than 10×109/L before procedure~* Any history of Severe renal or hepatic dysfunction (hepatic failure, cirrhosis, portal hypertension and active hepatitis);~* Neutropenia,~* thrombocytopenia;~* Known acute pancreatitis~* Arterial aneurysm, arterial/venous malformation and aorta dissection.~* Culprit lesion within the proximal 10 mm of the right or left coronary artery~* Saphenous vein grafts~* Lesion length \> 30 mm~* Involves a side branch ≥2.0 mm in diameter by visual estimate which requires treatment~* In-stent restenotic lesions~* Thombus-containing lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): Ticagrelor 90mg tablet, twice daily
- Clopidogrel (Type: EXPERIMENTAL): Clopidogrel 75mg tablet, daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of RRMS per McDonald criteria~* Received at least 12 months of continuous treatment with Tysabri monotherapy prior to initiation of Tecfidera. Note: continuous treatment with Tysabri is defined as treatment uninterrupted by other disease-modifying treatment.~* Initiated treatment with Tecfidera at least 12 months prior to enrollment into the study~* Patient has sufficient available medical records for data abstraction to meet the objectives of the study~Key Exclusion Criteria:~* Diagnosed with a progressive form of multiple sclerosis (MS) (progressive-relapsing, primary progressive, secondary progressive)~* Received treatment with any of the following after discontinuation of Tysabri and before initiation of treatment with Tecfidera (i.e., during washout period): interferon-beta, glatiramer acetate, fingolimod, teriflunomide, rituximab, alemtuzumab, ocrelizumab or any investigational compound for the treatment of RRMS~* Received BG00012, or other formulations of dimethyl fumarate, or Fumaderm® or compounded fumarates at any time prior to initiation of treatment with Tecfidera~* History of progressive multifocal leukoencephalopathy (PML) while on Tysabri or within 6 months of discontinuing treatment with Tysabri~NOTE: Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 12 years and above~* Clinical diagnosis of asthma according to the American Thoracic Society definition at least 6 months~* Pre-bronchodilator FEV1 ≥ 45% and ≤ 85% of predicted normal~* Patients with reversible airway obstruction~* Documented daily use of inhaled corticosteroids for ≥ 3 months~Exclusion Criteria:~* History of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures during the 2 years prior to Visit 2~* Hospitalized during previous 6 months for asthma~* Required emergency treatment more than once during previous 6 months for an asthma-related condition~* Intake of oral, rectal or parenteral glucocorticosteroid within 30 days of enrolment~* Respiratory infection affecting the asthma within 30 days

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Symbicort/inhaler (Type: ACTIVE_COMPARATOR): Symbicort BA MDI 2x160/4.5 μg twice daily
- Symbicort/inhaler (Type: ACTIVE_COMPARATOR): Symbicort AC pDMI 2x160/4.5 μg twice daily
- Budesonide/inhaler (Type: ACTIVE_COMPARATOR): Budesonide AC pMDI 2x160 μg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women with established causes of infertility and indications for the use of ART methods, according to the Order of the Ministry of Health of the Russian Federation On the use of assisted reproductive technologies, contraindications and limitations to their use No. 107 n dated August 30, 2012.~* Infertility due to female and/or male factor.~* Presence of ovaries accessible for aspiration of follicles.~* Anatomical and functional capability of uterus to bear pregnancy.~Exclusion Criteria:~* Women with established contraindications to the use of ART methods, according to the Order of the Ministry of Health of the Russian Federation On the use of assisted reproductive technologies, contraindications and limitations to their use No. 107 n dated August 30, 2012.~* Presence of pregnancy~* Hypersensitivity to follitropin alfa or excipients.~* Ovarian cysts (not associated with polycystic ovarian syndrome), uterine hemorrhage of unclear etiology~* Premature ovarian failure~* Presence of clinically significant systemic disease~* Presence of chronic cardiovascular, hepatic, renal or pulmonary disease~* Neoplasia~* Narcomania, alcoholism

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 43 Years
- Healthy Volunteers: f

Study Arms:
- Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH (Type: None): The ovarian stimulation (OS) protocols included monotherapy protocols with using follitropin alpha biosimilar only and antagonists/agonists of of gonadotropin-releasing hormone (GnRH): ganirelix, cetrorelix, triptorelin, buserelin.
- Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH (Type: None): The OS protocols included: mixed protocols (recombinant with addition of urinary-derived gonadotropins) and antagonists/agonists of GnRH (ganirelix, cetrorelix, triptorelin, buserelin), where follitropin alpha biosimilar used for at least 5 days during OS.
- Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH (Type: None): The OS protocols included: monotherapy protocols with using only follitropin alpha biosimilar and antagonists of GnRH.
- Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH (Type: None): The OS protocol included: monotherapy protocols with using only follitropin alpha biosimilar and agonists of GnRH.
- The overall protocols (Type: None): The OS protocols included: (1) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH, (2) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Ripening for Induction of Labor: Misoprostol Versus Oxytocin in Conjunction With Foley Balloon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant or surrogate is capable of giving informed consent~* Anticipated number - 50 patients with 25 in each study arm Female with singleton gestation, live intrauterine pregnancy~* Participant is undergoing an indicated induction of labor~* Participant is found to have cervical Bishop score ≤5 on initial cervical exam~* Participant has no medical or obstetrical contraindications to induction of labor~Exclusion Criteria:~* Participant has ≥2 painful contractions in 10 min in 2 subsequent 10 min periods~* Manufacturer's contraindications to misoprostol or oxytocin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxytocin (Type: ACTIVE_COMPARATOR): Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
- Misoprostol (Type: EXPERIMENTAL): Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC125-C223: TMC125 in HIV-1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 plasma viral load at screening \>1000 copies/ml~* Documented genotypic evidence of resistance to currently available NNRTIs~* Previous NRTI experience for at least 3 months~* 3 primary PI mutations at screening~Exclusion Criteria:~* Chronic HBV and/or HCV with elevated liver function tests \> 3x upper normal limits~* Any grade 3 or 4 toxicity according to the ACTG grading severity list (except for grade 3 glucose and asymptomatic triglyceride/cholesterol grade 3 or 4 elevation)~* Previous permanent discontinuation of any NNRTI due to cutaneous events.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed HCC in advanced stage; not suitable to surgery or local regional treatment; with at least one measurable lesion per RECIST 1.1~2. Failed or intolerable to at least one prior systemic treatment for advanced HCC~3. ECOG Performance Status of 0 or1~4. Child-Pugh Class A or B with 7 points~5. Life Expectancy of at least 12 weeks~6. HBV DNA\<500 IU/ml~7. Adequate organ function~8. Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 60 days for female subjects and 120 days for male subjects after the last dose of study drug~Exclusion Criteria:~1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC~2. Known liver transplant or plan to transplant~3. GI hemorrhage with 6 months~4. History or current brain metastases~5. Active known, or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SHR-1210 Q2W (Type: EXPERIMENTAL): Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
- SHR-1210 Q3W (Type: EXPERIMENTAL): Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete